TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01089855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Study: NCT01860170

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cohort 1-Bortezomib (Velcade ®)
Description: Conditioning Regimen: Fludarabine 30 mg/m2 on days -7, -6, -5, -4, -3 and -2; Busulfan 0.8 mg/kg, every 6 hours on days -3 and -2; Patients with matched unrelated donor also receive rATG (Thymoglobulin ®) 2 mg/kg on days -4, -3, -2 and -1.~Cyclophosphamide 50 mg/kg, in 500 mL NS over 2 hours on days +3 and +4. Concomitant hydration with NS with 20 mEq/L at 250 mL/hr starting 4 hours before and continuing until 24 hours after the second dose is given. Furosemide on as needed basis to maintain fluid balance is also given. It is important to avoid administration of any immunosuppressive drugs include steroids after day 0.~Bortezomib 0.7 mg/m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cohort 2-Bortezomib (Velcade ®)
Description: Conditioning Regimen: Fludarabine 30 mg/m2 on days -7, -6, -5, -4, -3 and -2; Busulfan 0.8 mg/kg, every 6 hours on days -3 and -2; Patients with matched unrelated donor also receive rATG (Thymoglobulin ®) 2 mg/kg on days -4, -3, -2 and -1.~Cyclophosphamide 50 mg/kg, in 500 mL NS over 2 hours on days +3 and +4. Concomitant hydration with NS with 20 mEq/L at 250 mL/hr starting 4 hours before and continuing until 24 hours after the second dose is given. Furosemide on as needed basis to maintain fluid balance is also given. It is important to avoid administration of any immunosuppressive drugs include steroids after day 0.~Bortezomib 1 mg/ m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cohort 3-Bortezomib (Velcade ®)
Description: Conditioning Regimen: Fludarabine 30 mg/m2 on days -7, -6, -5, -4, -3 and -2; Busulfan 0.8 mg/kg, every 6 hours on days -3 and -2; Patients with matched unrelated donor also receive rATG (Thymoglobulin ®) 2 mg/kg on days -4, -3, -2 and -1.~Cyclophosphamide 50 mg/kg, in 500 mL NS over 2 hours on days +3 and +4. Concomitant hydration with NS with 20 mEq/L at 250 mL/hr starting 4 hours before and continuing until 24 hours after the second dose is given. Furosemide on as needed basis to maintain fluid balance is also given. It is important to avoid administration of any immunosuppressive drugs include steroids after day 0.~Bortezomib 1.3 mg/m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3.
Study: NCT03645291

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Local insect allergen extracts skin test
Description: Every patient received both local and commercial insect allergen extracts but in blinded methods

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Local insect allergen extracts skin test
Description: Every patient received both local and commercial insect allergen extracts but in blinded methods
Study: NCT00098059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famciclovir
Description: Famciclovir sprinkle capsules, 25 mg and 100 mg, using OraSweet® syrup vehicle
Study: NCT04804852

Intervention type: OTHER
Intervention: sarcopenia assessment
Description: evaluation of sarcopenia by CT san at the C3 vertebrae
Study: NCT00759577

Intervention type: DRUG
Group type: OTHER
Intervention: Solifenacin
Description: 5mg and 10 mg, oral once daily
Study: NCT03177850

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACETAZOLAMIDE oral capsule
Description: Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
Study: NCT02653118

Intervention type: BIOLOGICAL
Intervention: V503

Intervention type: BIOLOGICAL
Intervention: V503

Intervention type: BIOLOGICAL
Intervention: GARDASIL
Study: NCT04014335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IONIS-FB-LRx
Description: Participants will receive IONIS-FB-LRx, by subcutaneous injection (SC) at Week 1 and every 4 weeks through Week 25. Optional 48-week Extension, with drug dosing continuing every 4 weeks.
Study: NCT00679484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil + candesartan cilexetil placebo
Description: Dosage form: tablet; frequency: daily; duration: 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil placebo + candesartan cilexetil
Description: Dosage form: tablets; frequency: daily; duration: 24 weeks
Study: NCT03562507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESK981
Description: ESK981: 160 mg (4 capsules) PO daily for 5 consecutive days followed by a 2-day off drug in each week, repeated weekly in 4-week (28-day) cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESK981
Description: ESK981: 160 mg (4 capsules) PO daily for 5 consecutive days followed by a 2-day off drug in each week, repeated weekly in 4-week (28-day) cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 480 mg/dose IV, Day 1 of each 28-day cycle
Study: NCT02785705

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: poliovirus vaccine
Description: Different vaccination schedules with bOPV, tOPV and cIPV would be provided for 6 arms respectively.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: poliovirus vaccine
Description: Different vaccination schedules with bOPV, tOPV and cIPV would be provided for 6 arms respectively.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: poliovirus vaccine
Description: Different vaccination schedules with bOPV, tOPV and cIPV would be provided for 6 arms respectively.
Study: NCT02152046

Intervention type: PROCEDURE
Intervention: ROP exam with spring loaded retractor
Study: NCT00693303

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Handwriting Training using My Scrivener
Description: Subjects received 20 minutes of training per week which included writing letters and words with the My Scivener device.
Study: NCT02368236

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Tailored Printout
Description: The Cancer Risk Intake System (CRIS) is a tablet-based program through which patients answer detailed questions about their colorectal cancer risk prior to an appointment. Tailoring algorithms in CRIS generate printed information for patients and their physicians summarizing their risk factors and matching them with guideline-based screening options.
Study: NCT04319536

Intervention type: OTHER
Intervention: no intervention
Description: self-sampling
Study: NCT02152046

Intervention type: PROCEDURE
Intervention: ROP exam with screw retractor
Study: NCT01477476

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anakinra
Description: Anakinra treatment will be given I.V. as a bolus of 2 mg/kg infused intravenously over 30 minutes followed by infusion of 2 mg/kg/hour for 4 hours.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: A placebo will be given to 7 subjects.
Study: NCT00709254

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: i.v. fentanyl
Description: single dose, 200 ug
Study: NCT02200575

Intervention type: DRUG
Intervention: Telmisartan
Study: NCT01369056

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advanced Adherence Counseling (AdvAdh)
Description: AdvAdh consists of 3 individual sessions (study months 0, 3, 6) -- patient-centered, non-judgmental, Motivational Interviewing- and theory-based, semi-structured, brief, candid conversations with a trained clinical care nurse using Next Step Counseling (NSC) approach. The intervention targets: 1) accurate information about antiretroviral treatment (ART) (mechanisms of HIV and antiretrovirals) and the development of mental imagery around it; 2) promotion of perceived sense of ease and efficacy in working ART regimen into the context of one's daily life and present life circumstances that may challenge drug use persistence; 3) identification, refinement of skills promoting ease of adhering to one's ART regimen across the diverse and challenges contexts.
Study: NCT00709254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 mL AeroLEF (500 µg/1 mL)
Description: A single dose of 3mL (500 µg/1 mL) of AeroLEF (Aerosolized Free and Liposome-Encapsulated Fentanyl)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 mL AeroLEF (500 µg/1 mL)
Description: A multiple doses of 3mL (500 µg/1 mL)of AeroLEF (Aerosolized Free and Liposome-Encapsulated Fentanyl)every 12 hours for a total of five doses over a 3 days
Study: NCT01056861

Intervention type: DRUG
Intervention: Botulinum Toxin A
Description: Not exceeding a total dose of 400 units, once every three months.

Intervention type: DRUG
Intervention: Botulinum Toxin A
Description: Not exceeding a total dose of 400 units, once every three months.
Study: NCT00460733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risedronate sodium
Description: Actonel® 35 mg (risedronate sodium) and 1000 mg of calcium and 400 UI of Vitamine D3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium & Vitamine D3
Description: 1000 mg of calcium and 400 UI of Vitamine D3
Study: NCT01747135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VTS-270
Study: NCT00350753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib and bevacizumab
Description: Erlotonib 150 mg daily bevacizumab 10 mg/kg every 14 days
Study: NCT02525458

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QAMS-containing PMMA
Description: Wear retainer with QMAS-containing PMMA on one side of retainer

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: QAMS-free PMMA
Description: Wear retainer with QMAS-free PMMA on other side of retainer
Study: NCT04033822

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cholecystectomy
Description: If patients are randomized to the intervention arm of the study; said patient will undergo corrective cholecystectomy surgery to correct cholecystitis as soon as possible with a goal of surgery within 6 hours of diagnosis.
Study: NCT03982316

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth Behavioral Migraine Management
Description: 1) Weekly online modules; 2) Monthly 50 minute telephone calls; 3) 3 15-minute telephone check ins.
Study: NCT00517426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetazolamide
Description: i.v. 500 mg of acetazolamide for the acute study and 500 mg of acetazolamide p.o. t.i.d. for two days
Study: NCT03575637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Patients who have failed first-line treatment of advanced gastric cancer receive second-line treatment with paclitaxel regimen and olanzapine 5 mg QD.
Study: NCT01310868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-ALA
Description: 5-ALA is used to generate tumour specific fluorescence as an aid to surgical resection of GBM, prior to the insertion of Gliadel wafers

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gliadel wafers
Description: The implantation of Carmustine Wafers (Gliadel) delivers carmustine- (3-bis 2-chloroethyl 1-1-nitrosourea (BCNU)) directly into the surgical cavity created after tumour resection.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy as normal based on standard clinical protocols determined by the neuro-oncologist
Description: 60Gy in 30 fractions (2Gy per fraction given once daily, five days per week (Monday-Friday) over 6 weeks. Radiotherapy delivered to gross tumour volume with 2-3cm margin. Standard treatment following neurosurgery for glioblastoma

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concomitant chemotherapy as normal based on standard clinical protocols determined by the neuro-oncologist
Description: temozolomide given alongside the radiotherapy at 75mg/m2 daily from the first day of radiotherapy, until the last day of radiotherapy, but for no longer than 49 days. Standard treatment following neurosurgery for glioblastoma

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy as normal based on standard clinical protocols determined by the neuro-oncologist
Description: Following a 4 week break after contomitant chemo/RT, temozolomide given 150-200mg/m2 TMZ 5/28 days for 6 cycles (dosage increase to 200mg/m2 on second and subsequent cycles dependent on haematological toxicity. Sites should follow local guidelines if different.). TMZ to be given on 5 consecutive days followed by 23 days with no TMZ, per cycle. Standard treatment following neurosurgery and concomitant chemo/RT for glioblastoma
Study: NCT01752413

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous gluconate 325mg
Description: Participants with low ferritin (\<30 micrograms/L (males) or \<20 micrograms/L (females)) will be asked to take two tablets of Ferrous Gluconate 325 mg (36 mg elemental iron) per day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition counseling
Description: All blood donors receive current dietary counseling recommending iron rich foods

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition counseling
Description: All blood donors receive current dietary counseling recommending iron rich foods
Study: NCT03823729

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elosan Cabin
Description: The Elosan Cabin is a closed, electrically insulated, biocompatible cabin for the short-term application of electrostatic high voltage. Patients assigned to the Group A will have 8 sessions in the Elosan cabin, with an interval of 3 to 4 days between sessions.
Study: NCT01713062

Intervention type: DEVICE
Intervention: Vitelene
Description: THA

Intervention type: DEVICE
Intervention: XLPE
Description: THA
Study: NCT04201912

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: saliva analysis for Toll like receptor activity
Description: Stimulated whole saliva will be obtained from patients and tested for Toll like receptor activity

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: saliva analysis for Toll like receptor activity
Description: Stimulated whole saliva will be obtained from patients and tested for Toll like receptor activity

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: saliva analysis for Toll like receptor activity
Description: Stimulated whole saliva will be obtained from patients and tested for Toll like receptor activity
Study: NCT00653315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol APAP
Description: Tablets, 37.5mg/325mg, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ultracet
Description: Tablets, 37.5mg/325mg
Study: NCT01815398

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation
Description: Neuropsychological Educational Approach to Remediation (NEAR) is an evidence based, manualized cognitive remediation program that targets cognitive deficits (eg memory, processing speed, executive functioning, working memory and attention) with the intent of improving daily functioning.NEAR is conducted in a small group setting, allowing for supportive social interaction while participants work at their own computer station on engaging computerized activities that are selected to address their unique profile of cognitive deficits. Then, as a group they discuss how their respective cognitive activities will help them achieve their vocational goals.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computer Skills Training
Description: Participants utilize an interactive software program that delivers tutorials, lessons, and practice sessions to develop computer skills for office based employment. During the learning activities, the clinician offers coaching and assistance in setting up computerized training exercises as needed.
Study: NCT02283944

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: Pulsed non-invasive brain stimulation using electromagnets
Study: NCT03317808

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Different exercise
Description: Evaluating the difference between Heavy slow resistance and traditional exercise, based on the SPADI score.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Different exercise
Description: Evaluating the difference between Heavy slow resistance and traditional exercise, based on the SPADI score.
Study: NCT02415725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: visualization of the architecture of superficial lymphatic network after Indocyanine Green injection
Study: NCT02689700

Intervention type: OTHER
Intervention: Blood samples
Description: Taking blood form the umbilical cord (fetal circulation) and from the vein of the corresponding mother.

Intervention type: OTHER
Intervention: Blood samples
Description: Taking blood form the umbilical cord (fetal circulation) and from the vein of the corresponding mother.
Study: NCT06559020

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kangroo mother care
Description: Kangaroo Mother Care (KMC) involves continuous skin-to-skin contact between the mother (or another family member) and the infant, aimed at promoting thermal regulation, breastfeeding, and bonding. In this study, KMC was initiated in the hospital and continued at home for a minimum of 8 hours daily.
Study: NCT04374773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol
Description: 2.5 mg PO administered once prior to and once after 1 week of hormone therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol
Description: 2.5 mg PO administered once prior to and once after 1 week of hormone therapy
Study: NCT00829530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg capsule
Description: 1 x 10 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Altace® 10 mg capsule
Description: 1 x 10 mg
Study: NCT06561997

Intervention type: DEVICE
Intervention: Robot-assisted
Description: received percutaneous pedicle screw fixation (PPSF) with robotic assistance

Intervention type: DEVICE
Intervention: Free-hand
Description: received percutaneous pedicle screw fixation (PPSF) without robotic assistance
Study: NCT00881634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine HCl/Pseudoephedrine HCl 5 mg/120 mg Tablets (Sandoz, USA)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zyrtec-D 12 Hour 5 mg/120 mg Extended Release Tablets (Pfizer, USA)
Study: NCT02703194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone:A starting dose of 0. 5-0. 8mg/(kg\*d) will be given. Following four-week period, the dose will be tapered gradually to 5mg/d until the end of 12 months of follow-up period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone:A starting dose of 0. 5-0. 8mg/(kg\*d) will be given. Following four-week period, the dose will be tapered gradually to 5mg/d until the end of 12 months of follow-up period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide
Description: Leflunomide:A starting dose of 20 mg/day will be given. This dose may be decreased to 10 mg/day at the discretion of the treating physician if minor adverse effects occur(e.g., liver enzyme elevations).
Study: NCT03714594

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10mg
Description: Dapagliflozin inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2) which are responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter mechanism causes blood glucose to be eliminated through the urine.\[

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10mg
Description: Dapagliflozin inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2) which are responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter mechanism causes blood glucose to be eliminated through the urine.\[

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saxagliptin 5mg
Description: Inhibits DPP-4 and slows inactivation of incretin hormones, thereby increasing blood concentrations and reducing fasting and postprandial glucose concentrations in a glucose-dependent manner in patients with type 2 diabetes mellitus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saxagliptin 5mg + Dapagliflozin 10 mg
Description: Please see Intervention 1 and 2
Study: NCT03692611

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skills TO Manage Pain (STOMP)
Description: 12 week pain self management (PSM) intervention incorporating social cognitive theory constructs.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: comparison group
Description: Participants in this arm will receive usual care as given by providers but no behavioral PSM intervention.
Study: NCT02226289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: bevacizumab with the latest received cytotoxic regimen
Study: NCT04173104

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/MR with [18F]PARPi
Description: One PET/MR study (with up to 3 scan times) with \[18F\]PARPi

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]PARPi
Description: Injection of \<100ug of \[18F\]PARPi prior to 1 PET/MR
Study: NCT02861300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-839
Description: Patients will receive CB-839 orally twice daily during each cycle. Each cycle will be 21 days long. Disease assessment will occur after cycle 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: capecitabine will be given orally twice daily for 14-21 days of cycles. Each cycle will be 21 days long. Disease assessment will occur after cycle 3.
Study: NCT00875667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: For patients with a creatinine clearance of ≥ 60 mL/min: 25 mg daily x 21 days of a 28 day cycle until disease progression or unacceptable toxicity.~For patients who have a moderate renal insufficiency (creatinine clearance is ≥ 30 mL/min but \< 60mL/min: 10 mg daily x 21 days of a 28 day cycle (Cycles 1 and 2). After Cycle 2, if the patient remains free of Grade 3 or Grade 4 toxicity, the dose will be increased to 15 mg daily x 21 days of a 28 day cycle until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Investigators choice single agent
Description: Investigators choice single agent - Chlorambucil, Rituximab, Cytarabine, Gemcitabine, or Fludarabine
Study: NCT02708511

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT